Your session is about to expire
← Back to Search
Bcl-2 Inhibitor GDC-0199 for Chronic Lymphocytic Leukemia
Study Summary
This trial is testing a combination of drugs to treat CLL that has returned or is unresponsive to treatment, or is previously untreated. The drugs work by blocking enzymes needed for cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What goals is this experiment attempting to achieve?
"The primary goal of this trial, monitored for up to two months post-treatment, is to determine the maximum tolerated dose of Bcl-2 inhibitor GDC-0199 in combination with obinutuzumab and ibrutinib (Phase Ib). Secondary objectives include tracking adverse events according to National Cancer Institute Common Terminology Criteria version 4.0; recording patients that reach a target dose of Bcl-2 inhibitor GDC-0199; and examining baseline prognostic factors through logistic regression analysis."
What is the limit of enrollees for this scientific experiment?
"Unfortunately, no more participants are being sought for this experiment. The study was first published on August 3rd 2015 and the most recent update took place November 16th 2022. However, there is a plethora of alternative studies recruiting; 1520 trials with CLL patients and 400 involving GDC-0199 inhibitors require enrolment currently."
What maladies does Bcl-2 Inhibitor GDC-0199 typically address?
"Bcl-2 Inhibitor GDC-0199 is traditionally used to treat small lymphocytic lymphoma, though its therapeutic applications extend to refractory follicular lymphoma and waldenstrom macroglobulinemia as well."
What prior research has been undertaken concerning the effects of Bcl-2 Inhibitor GDC-0199?
"Presently, there are 52 Phase 3 clinical trials and 400 active studies studying Bcl-2 Inhibitor GDC-0199. Out of the 13115 locations running these trials, most of them can be found in Edmonton, Alberta."
Are there still vacancies available for this research endeavor?
"This trial is not accepting participants as of the present moment. It was first put on clinicaltrials.gov in August 3rd 2015, and its last edit was November 16th 2022. For those looking for alternative studies, there are 1,520 trials searching for patients with chronic lymphocytic leukemia (CLL) and 400 recruiting individuals who need Bcl-2 inhibitor GDC-0199 treatment."
Share this study with friends
Copy Link
Messenger